The cardiac safety data is positive but expected given prior disclosures; no immediate catalyst. Monitor upcoming Phase 3 MIRACLE trial results and any regulatory interactions for meaningful stock-moving events.
Price Chart
Executive Summary
Moleculin Biotech announced publication of an abstract at the EHA 2026 Congress showing no clinically significant cardiotoxicity with Annamycin in a pooled analysis of 90 R/R AML patients. The data, from an independent Cleveland Clinic review, supports the drug's cardiac safety profile but does not alter the company's financial outlook or near-term regulatory path.
Key Facts
- Abstract accepted at EHA 2026 Congress highlighting cardiac safety of Annamycin.
- Independent review by Cleveland Clinic of 90 patients across 5 trials showed stable ejection fraction and no clinically significant left ventricular dysfunction.
- No financial guidance or material financial data provided in the filing.
Financial Impact
No financial impact reported in filing.
Risk Factors
- Phase 3 trial failure could materially impair stock value.
- Company requires additional financing to continue operations; no committed funding in place.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-016260 |
| Exhibit: ex_960914.htm | 0001437749-26-016260 |
| Document: 0001437749-26-016260-index-headers.html | 0001437749-26-016260 |
| Document: 0001437749-26-016260-index.html | 0001437749-26-016260 |
| Document: 0001437749-26-016260.txt | 0001437749-26-016260 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.19 | awaiting T+20 | — | $7.09 (+14.46%) |
Oct 16, 2026 10d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.09 (+2426.75%) |
Oct 9, 2026 16d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.09 (+1611.77%) |
Oct 5, 2026 21d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.09 (+1386.57%) |
Sep 29, 2026 27d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 29, 2026 27d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 28, 2026 28d ago | 8-K | $0.5690 | awaiting T+20 | — | $7.09 (+1145.17%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.09 (+1077.69%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.09 (+1242.11%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.09 (−1261.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers